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Abstract
Background
Although bariatric surgery is well established as an effective treatment for patients with obe-
sity and type 2 diabetes mellitus (T2DM), there exists reluctance to increase its availability
for patients with severe T2DM. The aims of this study were to examine the impact of bariatric
surgery on T2DM resolution in patients with obesity and T2DM requiring insulin (T2DM-Ins)
using data from a national database and to develop a health economic model to evaluate
the cost-effectiveness of surgery in this cohort when compared to best medical treatment
(BMT).
Methods and findings
Clinical data from the National Bariatric Surgical Registry (NBSR), a comprehensive data-
base of bariatric surgery in the United Kingdom, were extracted to analyse outcomes of
patients with obesity and T2DM-Ins who underwent primary bariatric surgery between 2009
and 2017. Outcomes for this group were combined with data sourced from a comprehensive
literature review in order to develop a state-transition microsimulation model to evaluate
cost-effectiveness of bariatric surgery versus BMT for patients over a 5-year time horizon.
The main outcome measure for the clinical study was insulin cessation at 1-year post-sur-
gery: relative risks (RR) summarising predictive factors were determined, unadjusted, and
after adjusting for variables including age, initial body mass index (BMI), duration of T2DM,
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and weight loss. Main outcome measures for the economic evaluation were total costs, total
quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) at will-
ingness-to-pay threshold of GBP£20,000.
A total of 2,484 patients were eligible for inclusion, of which 1,847 had 1-year follow-up
data (mean age of 51 years, mean initial BMI 47.2 kg/m2, and 64% female). 67% of patients
no longer required insulin at 1-year postoperatively: these rates persisted for 4 years. Roux-
en-Y gastric bypass (RYGB) was associated with a higher rate of insulin cessation (71.7%)
than sleeve gastrectomy (SG; 64.5%; RR 0.92, confidence interval (CI) 0.86–0.99) and
adjustable gastric band (AGB; 33.6%; RR 0.45, CI 0.34–0.60; p < 0.001). When adjusted for
percentage total weight loss and demographic variables, insulin cessation following surgery
was comparable for RYGB and SG (RR 0.97, CI 0.90–1.04), with AGB having the lowest
cessation rates (RR 0.55, CI 0.40–0.74; p < 0.001). Over 5 years, bariatric surgery was cost
saving compared to BMT (total cost GBP£22,057 versus GBP£26,286 respectively, incre-
mental difference GBP£4,229). This was due to lower treatment costs as well as reduced
diabetes-related complications costs and increased health benefits. Limitations of this study
include loss to follow-up of patients within the NBSR dataset and that the time horizon for
the economic analysis is limited to 5 years. In addition, the study reflects current medical
and surgical treatment regimens for this cohort of patients, which may change.
Conclusions
In this study, we observed that in patients with obesity and T2DM-Ins, bariatric surgery was
associated with high rates of postoperative cessation of insulin therapy, which is, in turn, a
major driver of overall reductions in direct healthcare cost. Our findings suggest that a strat-
egy utilising bariatric surgery for patients with obesity and T2DM-Ins is cost saving to the
national healthcare provider (National Health Service (NHS)) over a 5-year time horizon.
Author summary
Why was this study done?
• Bariatric or weight loss surgery can dramatically improve type 2 diabetes mellitus
(T2DM) in patients with obesity, allowing many patients to stop medicines for T2DM
completely.
• Unfortunately, there are limited resources for performing bariatric surgery. Patients
with severe T2DM, who require daily insulin injections, are at risk of being considered
lower priority than those with T2DM managed by tablet medications. This is because
some small studies have suggested that T2DM requiring insulin (T2DM-Ins) is too
advanced to be reversed by surgery.
• The aims of this study were to see how effective bariatric surgery is in patients with obe-
sity and T2DM-Ins, as well as to determine if performing surgery in this group is cost-
effective over a 5-year period.
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What did the researchers do and find?
• We used data from a nationwide registry of patients undergoing bariatric surgery in the
UK to examine the effect of surgery on patients that require insulin for T2DM. We
found that certain types of procedure (Roux en Y gastric bypass (RYGB) and sleeve gas-
trectomy (SG)) were associated with excellent rates of stopping insulin (approximately
two-thirds of patients).
• We then devised an economic model to compare the costs of this type of surgery with
the costs of treating patients using optimal medicines for T2DM. We found that per-
forming surgery was less costly and more effective for the national healthcare provider
(National Health Service (NHS)), over a 5-year timeline.
What do these findings mean?
• These findings are important because they suggest that patients with obesity and
T2DM-Ins are good candidates for bariatric surgery.
• Offering bariatric surgery to such patients could improve their health and provide cost
savings to national healthcare payers.
Introduction
Over the last decade, bariatric surgery has been shown to be an effective treatment for type 2
diabetes mellitus (T2DM) in patients with obesity [1,2]. Surgery is associated with superior
improvement in hyperglycaemia as compared to best medical treatment (BMT), an effect that
is sustained for at least 5 years [3–6]. The improvement in hyperglycaemia is associated with a
reduction in mortality [7,8] and diabetes-related complications [9,10]. Improvement in T2DM
following bariatric surgery is mediated by both weight loss–dependent and weight loss–inde-
pendent mechanisms [11,12].
T2DM is, however, a progressive, heterogenous disorder with a spectrum of severity
[13,14]. To date, the major randomised controlled trials investigating the clinical outcomes of
bariatric surgery for T2DM have focused predominantly on patients with more recent onset
disease not requiring insulin, as opposed to patients with disease of longer duration requiring
insulin [3,4]. To date, there has only been one study, a regional registry analysis, focused on
patients who require insulin for their T2DM [15]. A number of retrospective studies have ana-
lysed the factors associated with successful diabetes remission following bariatric surgery [16–
18]. These studies suggest that patients with more severe T2DM (defined as requiring insulin
treatment and/or of long duration) are less likely to experience sustained remission of hyper-
glycaemia following bariatric surgery. These disappointing findings may explain reluctance in
some settings towards surgical treatment for patients with obesity and longer standing T2DM
requiring insulin (T2DM-Ins): the national commissioning guidelines in Scotland, for exam-
ple, permit referral for bariatric surgery only for patients with new-onset T2DM (less than 5
years) [19].
In addition to the clinical benefits of bariatric surgery for individual patients with obesity
and T2DM, a number of studies have analysed the healthpayer costs of bariatric surgery [20–
22]. Although these studies suggest that surgery is cost-effective as compared to medical
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management, to date no economic evaluations focus on patients with T2DM-Ins. Moreover,
many of these existing economic analyses predate the wide-scale adoption of newer antidia-
betic medications such as glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-
glucose transport protein 2 (SGLT2) inhibitors—medications which have recently changed the
landscape of treatment for patients with more severe T2DM [23]. Though effective, these new
medications have significant cost implications. There is a need, therefore, to investigate the
clinical outcomes of bariatric surgery in a large cohort of patients with T2DM-Ins and evaluate
the cost-effectiveness of a surgical strategy in this cohort.
The purposes of this study were two-fold: firstly, to evaluate clinical outcomes following
bariatric surgery in patients with obesity and T2DM-Ins using a UK registry dataset which rep-
resents the largest cohort published to date; and secondly, to combine the data with other rele-
vant sources to develop a model-based economic evaluation to assess the cost and cost-
effectiveness of bariatric surgery versus BMT in this cohort.
Methods
The clinical study analysis and cost-effectiveness study framework were planned at the time of
study conception, although no formal prospective analysis plan was recorded. For the clinical
study, this included the variables that would be adjusted for during regression analysis. For the
cost-effectiveness analysis, the model was designed, and data inputs agreed prior to running
the model: these data inputs would include those derived from previous studies as well as the
present clinical study. After the base case model had been run, and in response to peer review-
ers’ comments, three alternative scenario analyses were additionally constructed and run: two
for different ethnicities and one with an adjusted hypoglycaemia rate in the BMT group (see
S1 Text). This study is reported as per the Consolidated Health Economic Evaluation Report-
ing Standards (CHEERS) guideline (S1 CHEERS Checklist).
Design of the clinical study
Data source and study population. To evaluate the clinical outcomes of patients with
obesity and severe T2DM, as well as prognostic factors predictive of clinical outcomes, we
extracted data from the National Bariatric Surgical Registry (NBSR). The NBSR is a bespoke
database for the prospective collection of demographic, perioperative, and clinical outcome
data for patients with obesity undergoing bariatric surgery in the UK and Republic of Ireland
[24]. The details of the demographic and clinical data recorded in this database as well as the
data quality are detailed in previous publications [25,26]. Fully anonymised data were
extracted from the registry from patients that had previously consented to the collection of
their data.
Diabetes status in NBSR is recorded preoperatively and at every postoperative visit as fol-
lows: no indication of T2DM; impaired glycaemia or impaired glucose tolerance (diet con-
trolled); oral hypoglycaemics only; or insulin treatment (insulin with or without additional
hypoglycaemic medications). As insulin use has consistently been identified as a strong nega-
tive predictor of remission of T2DM after bariatric surgery [16–18], we focused on patients
that were using insulin for T2DM preoperatively (T2DM-Ins).
From the database, we identified all patients with T2DM-Ins who had undergone primary
Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), or adjustable gastric band (AGB)
between 1 January 2009 and 31 May 2017. As the majority of patients have several follow-up
episodes recorded on NBSR, data were selected as follows: for outcomes at 1 year, only patients
with a follow-up appointment between 6- and 24-months post-surgery were included, and
data were extracted from the clinic appointment closest to the 1-year point after surgery; for
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longer-term outcomes, data were extracted from the final recorded clinic appointment, with
exclusion of any patients with less than 2 years’ follow-up. For diabetes status over time, all
patients with any follow-up visit were included.
Ethics statement
The data holder NBSR complied with local ethics guidelines and use of this dataset for research
purposes conformed with UK legislation and was approved by the Health Research Authority
(17/CAG/0023).
Analytical approach
Data are presented as mean with standard deviation or number with percentage of total in
parentheses.
Percent weight loss (%WL) was calculated as percent of total weight lost using the following
formula:
%WL ¼ 100� ðInitial Weight   Follow  up WeightÞ=Initial Weight
Percent excess weight loss (%EWL) was calculated based on an optimum body mass index
(BMI) of 25 kg/m2, using the following formula:
%EWL ¼ 100� ðInitial Weight   Follow  up WeightÞ=ðInitial Weight   OptimumWeightÞ
Comparison of baseline factors and outcomes by procedure was initially carried out by
analysis of variance (means), quantile regression (medians), or chi-squared tests as appropri-
ate. Further adjusted comparison of factors predicting insulin cessation following surgery were
made using Poisson regression to generate relative risk (RR) ratios, 95% confidence intervals
(CIs) and p-values using PROC GENMOD, SAS software version 9.4 (SAS Institute Inc., Cary,
North Carolina, United States of America). Robust standard errors were estimated accounting
for clustering by hospital, and an offset term was included based on follow-up time. For proce-
dure type, RYGB was chosen as the reference category. Baseline factors used for adjustment
were age, gender, initial BMI, smoking, number of comorbidities, duration of diabetes, and
ethnicity. Additionally, further models adjusted for postoperative change in weight (with ini-
tial BMI removed), in order to assess any potential contributions to improvement in T2DM
mediated through weight loss–independent mechanisms of the different operations. This anal-
ysis was included because it has been demonstrated that some bariatric procedures (such as
RYGB) may be associated with greater weight loss–independent improvements in T2DM as
compared to others [11,12]. Age and weight-related variables (BMI, weight loss, and excess
weight loss) are presented within categories, but additional models were fitted with them as
continuous variables.
Design of the health economic model
We developed a model-based management protocol in order to compare the costs and effects
of a strategy of surgical intervention versus BMT for patients with obesity and T2DM-Ins, over
a 5-year timeline horizon. As detailed in full in S1 Text, individual patients with T2DM-Ins
were simulated based on characteristics from the UK NBSR dataset and then duplicated to cre-
ate an identical clone. In the model, one clone was treated with BMT, while the other was
treated with bariatric surgery. This strategy ensures that the treatment comparisons are not
being influenced by differences in patient characteristics but only based on the treatments
received. Each clone or “patient” was then put through the model, and the costs and health
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outcomes were amassed for all patients in each treatment arm. The model is developed as a
state-transition patient-level simulation with 1-year cycle length.
Model inputs
The data from the NBSR as presented in this paper were utilised to inform baseline patient
characteristics for the population (see “Model Inputs,” S1 Text).
For the purposes of this evaluation, given the inferior efficacy of AGB when compared to
RYGB and SG in T2DM improvement (see results below), we modelled that patients in the
surgical group would only undergo either RYGB or SG. We assumed, based on recent UK pro-
cedure prevalence data [27], that 58% would undergo RYGB and 42% SG.
The BMT regimen (which includes nutritional counselling) was determined from the latest
guidelines from the American Diabetes Association and European Association for Study of
Diabetes, and expert consensus (see S1 Text) [23]. All costs and outcomes after the first year
were discounted 3.5% per year in line with National Institute for Health and Care Excellence
(NICE) recommendations.
The model is fully described in S1 Text, including the sources from which all model inputs
were derived.
Model outcomes
The model calculates the following outcomes:
1. Total costs (consisting of treatment acquisition costs, cost of adverse events, and cost of dis-
ease-related complications);
2. Life-years gained;
3. Quality-adjusted life year (QALY), an outcome that captures life expectancy and quality of
life in one measure, and cost per QALY;
4. Incremental costs: the difference in the total cost between bariatric surgery and BMT;
5. Incremental QALYs: the difference in the total QALYs gained between bariatric surgery
and BMT;
6. Incremental cost-effectiveness ratio (ICER), which is calculated by dividing the difference
in cost between two arms (incremental cost) by the difference in QALYs (incremental
QALYs). In general, the treatment option is considered cost-effective when the ICER is
below a willingness-to-pay threshold of GBP£20,000/QALY [28];
7. Net monetary benefit (NMB): the value of bariatric surgery in monetary terms under the
willingness-to-pay threshold of GBP£20,000/QALY for a unit of benefit. It is calculated as
NMB = Δ QALY�λ − Δ cost, where λ is willingness-to-pay threshold in England (GBP
£20,000/QALY). Intervention is considered cost-effective when NMB is greater than 0;
8. Net health benefit (NHB): the value of bariatric surgery in terms of health benefit corrected
for the incremental costs divided by willingness-to-pay threshold. NHB is calculated as
NHB = Δ QALY − Δ cost/λ. Treatment is considered cost-effective when NHB is greater
than 0. Both NMB and NHB are presented at willingness-to-pay thresholds of GBP£20,000/
QALY.
9. Probabilistic sensitivity analysis–cost-effectiveness plane, which reports an average ICER
with a 95% CI and the probability that the intervention is cost-effective.
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Results
Clinical study
Description of cohort. A total of 3,261 surgical patients with T2DM-Ins were identified
from the NBSR as having had primary RYGB, SG, or AGB during the designated time frame
(Fig 1). Of these, 2,484 (76.2%) had at least 1 follow-up visit recorded in the NSBR, with 1,847
having one visit between 6- and 24-months post-surgery (“1-year follow-up”). Of these, 1,313
(71.1%) underwent RYGB, 397 (21.5%) SG, and 137 (7.4%) AGB. Demographic data for these
patients are summarised in Table 1.
Primary procedures were defined as RYBG, SG, or AGB. Acceptable data required all the
following: nonzero age, initial weight 70 to 400 kg, height 1 to 2 m, and duration of T2DM
recorded.
Clinical outcomes. At 1-year follow-up (mean of 355 days post-procedure), the mean per-
centage weight loss was 27.4%, with evidence of differential weight loss between surgical
groups (p< 0.001; Table 2).
Overall, approximately one-third (32.7%) of the total cohort were still using insulin at 1
year, with another third (33.5%) no longer recorded as having T2DM. There was significant
variation in T2DM status by procedure (p< 0.001); with 33.6% having ceased use of insulin in
the AGB group compared to 64.5% and 71.7% in the SG and RYGB groups, respectively, and a
smaller proportion of patients assessed as having no indication of T2DM following AGB
(5.1%) than SG and RYGB (30.0% and 37.6%, respectively).
Follow-up of over 2 years (mean 1,132 days, maximum 3,274 days) was available for 857
patients, of whom 605 (70.6%) underwent RYGB, 156 (18.2%) SG, and 96 (11.2%) AGB
(Table 3). Weight loss again varied by procedure (p< 0.001) with levels broadly similar to
those reported at 1-year follow-up. For diabetes status, differences between procedures were
still apparent (p< 0.001), with a wider gap now seen between the percentage of patients with
no indication of T2DM in the RYGB (42.2%) and SG (26.9%) groups.
Fig 2 summarises T2DM status over 4 years, in 3-month periods, for all surgical patients
with follow-up within those periods only. Prevalence of insulin use reached a plateau at around
19 to 24 months, stabilising at this level up to 4 years after surgery. Similarly, BMI reached a
plateau at around 13 to 18 months, stabilising over the next 4 years (Fig 3).
Prediction of insulin cessation by baseline factors. Insulin cessation was more prevalent
in patients undergoing RYGB than in patients undergoing SG (RR 0.92, 95% CI 0.86 to 0.99,
p = 0.02) or AGB (RR 0.45, 95% CI 0.34 to 0.60, p< 0.001) (Table 4). Male patients were more
likely to cease insulin use after surgery (RR 1.14, 95% CI 1.07 to 1.23, p< 0.001). There was no
evidence of different insulin cessation rates by number of comorbidities (RR 1.02, 95% 0.94 to
1.11 for 2 or more versus none). Patients with shorter T2DM duration were more likely to
cease insulin (RR 1.40, 95% CI 1.29 to 1.53, p< 0.001, for patients with duration <5 years as
compared to those with duration >10 years). When adjusted for other baseline demographic
factors, procedure, gender, and duration of diabetes were all independent predictors of cessa-
tion of insulin use after surgery (p< 0.001).
Prediction of insulin cessation by subsequent change in weight. Lower %WL and
%EWL at follow-up was associated with significantly poorer rates of insulin cessation
(Table 5). To investigate whether the relative improvement in insulin cessation outcomes con-
ferred by RYGB was related to weight loss, the model was fitted adjusting for all baseline fac-
tors except initial BMI, with either %WL (WL model) or %EWL (EWL model) included. Once
weight loss was adjusted for using either model, SG was no longer associated with statistically
inferior rates of insulin cessation compared to RYGB (RR 0.97, 95% CI 0.90 to 1.04, p = 0.37
for WL model and RR 0.97, 95% CI 0.91 to 1.04, p = 0.44 for EWL model). Even when adjusted
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for weight loss, however, AGB was still associated with poorer rates of insulin cessation than
RYGB (RR 0.55, 95% CI 0.40 to 0.74 for WL model and RR 0.56, 95% CI 0.42 to 0.73 for EWL
model, p< 0.001).
Fig 1. Flowchart to illustrate selection of surgical patients from NBSR database for the clinical study. NBSR,
National Bariatric Surgical Registry.
https://doi.org/10.1371/journal.pmed.1003228.g001
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To assess whether nonlinearity between age, %WL, %EWL, and insulin cessation would
impact the RR for insulin cessation conferred by the different operations, sensitivity analyses
fitted alternative models using quadratic terms. These adjusted models generated approxi-
mately the same RRs, consistently finding AGB to be inferior to RYGB and SG for insulin ces-
sation (S1 Table).
Cost and cost-effectiveness analysis
Detailed results are presented in S1 Text. S2–S15 Tables detail model inputs, S16 Table pro-
vides additional results, and S17–S19 Tables give uncertainty and scenario analyses. S1–S3 Figs
illustrate model design and patient flow through the models, while S4 and S5 Figs provide
additional results. The most important economic-related outcomes are summarised and pre-
sented below.
Treatment acquisition costs. Table 6 summarises the results in terms of cumulative aver-
age treatment acquisition cost per patient over 5 years for surgery and BMT. Every patient in
the bariatric surgery arm will follow the bariatric surgery costs (S10 Table), whereby their first-
year treatment will have one-off surgery costs and subsequent drug costs. Every patient in the
BMT arm will have drug costs as detailed in S11 Table which may vary each year, depending
on whether treatment strategy stays the same (if hemoglobin A1c (HbA1c) falls below 8%) or
Table 1. Baseline demographic data for surgical patients by procedure (n = 1,847).
All AGB SG RYGB
Number of patients n (%) 1,847 (100) 137 (7.4) 397 (21.5) 1,313 (71.1)
Age (years) Mean (SD) 51.1 (9.4) 52.6 (9.6) 52.2 (10.1) 50.7 (9.1)
Initial weight (kg) Mean (SD) 132.7 (24.5) 130.1 (21.8) 138.3 (28.8) 131.2 (23.0)
Median (IQR) 131.0 (115.3–148.1) 129.0 (113.8–143.6) 134.7 (119.0–153.6) 129.9 (115.0–145.8)
Initial BMI (kg/m2) Mean (SD) 47.2 (7.3) 47.0 (6.3) 49.1 (8.7) 46.6 (6.9)
Median (IQR) 46.3 (41.8–51.5) 46.9 (41.8–51.5) 47.7 (42.8–54.4) 46.1 (41.6–50.7)
Sex
Men n (%) 667 (36.1) 44 (32.1) 156 (39.3) 467 (35.6)
Smoking�
Never n (%) 984 (56.1) 62 (49.6) 238 (63.0) 684 (54.7)
Ex n (%) 642 (36.6) 51 (40.8) 116 (30.7) 475 (38.0)
Current n (%) 127 (7.2) 12 (9.6) 24 (6.4) 91 (7.3)
Duration of T2DM
0–5 years n (%) 454 (24.6) 29 (21.2) 100 (25.2) 325 (24.8)
6–10 years n (%) 568 (30.8) 42 (30.7) 116 (29.2) 410 (31.2)
>10 years n (%) 825 (44.7) 66 (48.2) 181 (45.6) 578 (44.0)
Number of comorbidities
0 n (%) 525 (28.4) 42 (30.7) 112 (28.2) 371 (28.3)
1 n (%) 623 (34.2) 45 (32.9) 133 (33.5) 454 (34.6)
2 or more n (%) 690 (37.4) 50 (36.5) 152 (38.3) 488 (37.2)
Ethnicity�
White n (%) 1,591 (90.4) 125 (94.0) 328 (87.0) 1,138 (91.0)
Nonwhite n (%) 169 (9.6) 8 (6.0) 49 (13.0) 112 (9.1)
�Expressed among those with a recording in each category. Missing data for the following categories: n = 94 (5.1%) had no smoking data record; n = 87 (4.7%) had no
ethnicity recorded.
AGB, adjustable gastric band; BMI, body mass index; IQR, interquartile range; RYGB, Roux-en-Y gastric bypass; SD, standard deviation; SG, sleeve gastrectomy; T2DM,
type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pmed.1003228.t001
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is modified (S5 Table). If a patient dies before the end of the 5-year term (from diabetes-related
deaths or other deaths), they will no longer contribute to the acquisition costs or any other
costs (see S2 Fig for patient flow).
As shown, when compared to BMT, bariatric surgery is predicted to a lead to treatment
acquisition cost saving over a 5-year time horizon.
Adverse events. In relation to costs directly attributable to adverse events of treatment
(i.e., in the surgical arm costs of surgical complications plus adverse drug reactions; and in the
Table 2. Outcomes for surgical patients at 1-year follow-up by procedure (n = 1,847).
All (n = 1,847) AGB (n = 137) SG (n = 397) RYGB (n = 1,313) p-value��
Days since procedure Mean (SD) 354.7 (89.1) 362.6 (80.0) 351.2 (91.5) 354.9 (89.2) 0.43
Readmission within 30 days�
No n (%) 1,718 (94.5) 127 (94.8) 374 (95.4) 1,217 (94.2) 0.64
Yes n (%) 100 (5.5) 7 (5.2) 18 (4.6) 75 (5.8)
Weight loss
%WL Mean (SD) 27.4 (9.3) 15.8 (9.0) 25.1 (9.2) 29.4 (8.2) <0.001
Median (IQR) 27.6 (21.6–33.6) 15.5 (10.3–21.3) 24.9 (19.3–30.4) 29.5 (24.1–34.8) <0.001
%EWL Mean (SD) 61.5 (22.9) 35.0 (20.1) 54.7 (22.8) 66.3 (20.8) <0.001
Median (IQR) 60.6 (47.0–75.3) 34.6 (21.8–49.7) 53.0 (39.8–67.4) 64.9 (52.7–78.7) <0.001
Diabetes status
No indication of T2DM n (%) 619 (33.5) 7 (5.1) 119 (30.0) 493 (37.6) <0.001
Impaired fasting glycaemia n (%) 77 (4.2) 4 (2.9) 19 (4.8) 54 (4.1)
Oral hypoglycaemics n (%) 548 (29.7) 35 (25.6) 118 (29.7) 395 (30.1)
Insulin n (%) 603 (32.7) 91 (66.4) 141 (35.5) 371 (28.3)
�Missing data for n = 29 (1.6%) patients
��p-value for tests of heterogeneity between procedure type (ANOVA, comparison of medians using quantile regression, or chi-squared test).
%EWL, percent excess weight loss; %WL, percent weight loss; AGB, adjustable gastric band; ANOVA, analysis of variance; IQR, interquartile range; RYGB, Roux-en-Y
gastric bypass; SD, standard deviation; SG, sleeve gastrectomy; T2DM, type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pmed.1003228.t002
Table 3. Outcomes for surgical patients at final follow-up by procedure (n = 857).
All AGB SG RYGB p-value�
Number of patients n (%) 857 (100) 96 (11.2) 156 (18.2) 605 (70.6)
Days since procedure Mean (SD) 1,131.5 (466.9) 1,455.2 (551.3) 1,062.8 (413.6) 1,097.9 (445.3) <0.001
Weight loss
%WL Mean (SD) 27.1 (11.1) 17.2 (10.0) 24.7 (11.5) 29.3 (10.1) <0.001
Median (IQR) 27.3 (19.5–34.9) 17.0 (10.8–24.2) 23.5 (17.4–32.2) 29.1 (22.6–36.3) <0.001
%EWL Mean (SD) 59.7 (25.0) 37.7 (22.6) 53.3 (26.1) 64.9 (22.8) <0.001
Median (IQR) 59.3 (43.6–76.6) 36.5 (24.3–51.0) 51.0 (35.7–70.1) 64.4 (49.8–80.2) <0.001
Diabetes status
No indication of T2DM n (%) 314 (36.6) 17 (17.7) 42 (26.9) 255 (42.2) <0.001
Impaired fasting glycaemia n (%) 40 (4.7) 3 (3.1) 10 (6.4) 27 (4.5)
Oral hypoglycaemics n (%) 270 (31.5) 24 (25.0) 50 (32.1) 196 (32.4)
Insulin n (%) 233 (27.2) 52 (54.2) 54 (34.6) 127 (21.0)
�p-value for tests of heterogeneity between procedure type (ANOVA, comparison of medians using quantile regression, or chi-squared test).
%EWL, percent excess weight loss; %WL, percent weight loss; AGB, adjustable gastric band; ANOVA, analysis of variance; IQR, interquartile range; RYGB, Roux-en-Y
gastric bypass; SD, standard deviation; SG, sleeve gastrectomy; T2DM, type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pmed.1003228.t003
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BMT group the adverse drug reactions), the cumulative costs for the bariatric surgical group
were GBP£1,152, and for the group undergoing BMT, GBP£955. This represents an incremen-
tal difference of GBP£197 in favour of BMT over a 5-year period.
Reductions in disease-related complications. Based on the assumptions of the effects of
BMT and bariatric surgery on modifying HbA1c and BMI (both of which were the two most
important predictors of T2DM complications, see S1 Text), bariatric surgery leads to a lower
cumulative incidence of diabetes-related complications (Table 7) and consequently lower cost
for the management of these complications (Table 8).
Summary of total costs
In summary, bariatric surgery is predicted to result in a total cost saving of GBP£4,229 when
compared to BMT over a 5-year time horizon (Table 9).
Unlike medication costs, the costs of surgery are incurred at the start of the model and not
spread over the 5-year period; hence, at approximately 3.5 years after surgery, the total cost of
Fig 2. T2DM status in patients over time since bariatric procedure. Percentage of patients with each T2DM status among those with a follow-up visit during each
time period from bariatric procedure. Numbers at each visit were the following: month 0 to 6 n = 2,150; month 7 to 12 n = 1,446; month 13 to 18 n = 1,114; month 19 to
24 n = 639; month 25 to 30 n = 633; month 31 to 36 n = 251; month 37 to 42 n = 190; month 43 to 48 n = 108. T2DM, type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pmed.1003228.g002
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a patient treated with bariatric surgery equals the total cost of a patient treated with BMT,
whereby from that breakeven point, bariatric surgery becomes the cost-saving option.
Cost-effectiveness. As shown in Table 10, from a cost-effectiveness perspective, when
compared to BMT, bariatric surgery is predicted to lead to a lower cumulative incidence of
diabetes-related complications and is consequently associated with improved life expectancy
and measures of quality of life.
Probabilistic sensitivity analysis demonstrated that bariatric surgery consistently leads to
cost savings when compared with BMT and in more than 50% of cases to positive incremental
health benefits (S16 Table and S5 Fig).
Discussion
We used the UK NBSR, a nationwide registry of patients undergoing bariatric surgery, to
assess clinical outcomes of surgery for patients with obesity and T2DM-Ins. Our findings were
then combined with data from the literature to develop a model to analyse cost-effectiveness of
bariatric surgery for this cohort, when compared to BMT. The study demonstrated that bariat-
ric surgery in patients with obesity and T2DM-Ins was associated with good medium-term
Fig 3. BMI in patients over time since bariatric procedure. Box and whisker plot (median and IQR) to illustrate BMI of patients among those with
a follow-up visit during each time period from bariatric procedure. Whiskers represent the upper and lower adjacent values, with dots showing
observations beyond these values. Numbers at each visit were the following: month 0 to 6 n = 2,133; month 7 to 12 n = 1,442; month 13 to 18
n = 1,112; month 19 to 24 n = 637; month 25 to 30 n = 633; month 31 to 36 n = 250; month 37 to 42 n = 189; month 43 to 48 n = 108. BMI, body mass
index; IQR, interquartile range.
https://doi.org/10.1371/journal.pmed.1003228.g003
PLOS MEDICINE Clinical and cost-effectiveness of bariatric surgery in patients with severe T2DM
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003228 December 7, 2020 12 / 22
Table 4. Unadjusted and adjusted RRs for insulin cessation at follow-up by baseline factors (n = 1,847).
n % on insulin at 6–24 month follow-up RR (95% CI) unadjusted RR (95% CI) mutually adjusted
Operation type
AGB 137 66.4% 0.45 (0.34–0.60) 0.46 (0.35–0.61)
RYGB 1,313 28.3% 1 1
SG 397 35.5% 0.92 (0.86–0.99) 0.91 (0.84–0.98)
p-value� <0.001 <0.001
Age (years)
17–39 222 35.6% 0.89 (0.81–0.98) 0.90 (0.83–0.97)
40–49 540 30.4% 1 1
50–59 718 31.9% 0.95 (0.87–1.04) 0.98 (0.90–1.06)
60+ 367 35.7% 0.91 (0.81–1.01) 0.97 (0.88–1.07)
p-value† 0.96 0.13
Sex
Female 1,180 35.9% 1 1
Male 667 26.8% 1.14 (1.07–1.23) 1.14 (1.06–1.23)
p-value� <0.001 <0.001
Initial BMI
40 or less 284 34.5% 1.04 (0.89–1.22) 1.02 (0.87–1.19)
40–45 479 35.3% 1 1
45–50 490 32.0% 1.04 (0.95–1.13) 1.02 (0.94–1.11)
50–55 324 31.2% 1.05 (0.96–1.14) 1.03 (0.95–1.12)
55–60 176 31.8% 1.09 (0.96–1.23) 1.10 (0.98–1.24)
60 or more 94 23.4% 1.14 (0.99–1.32) 1.11 (0.96–1.27)
p-value† 0.31 0.31
Smoking
Never 984 32.4% 1 1
Ex vs. never 642 32.9% 1.01 (0.94–1.08) 1.00 (0.93–1.07)
Current vs. never 127 25.2% 1.12 (1.01–1.23) 1.09 (0.98–1.27)
p-value� 0.051 0.10
Comorbidities
0 525 36.2% 1 1
1 632 30.2% 1.06 (0.98–1.16) 1.07 (1.00–1.15)
2 or more 690 32.2% 1.02 (0.94–1.11) 1.03 (0.95–1.12)
p-value� 0.70 0.50
T2DM duration (years)
0–5 454 19.8% 1.40 (1.29–1.53) 1.39 (1.28–1.50)
6–10 568 27.3% 1.31 (1.19–1.44) 1.29 (1.17–1.42)
>10 years 825 43.4% 1 1
p-value� <0.001 <0.001
Ethnicity
White 1,591 32.4% 1 1
Nonwhite 169 32.5% 1.06 (0.96–1.18) 1.09 (1.00–1.20)
p-value� 0.40 0.21
�p-values test for heterogeneity between categories.
†p-values test for linear trend derived from model where age and BMI were fitted as continuous variables.
AGB, adjustable gastric band; BMI, body mass index; CI, confidence interval; RR, relative risk; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; T2DM, type 2
diabetes mellitus.
https://doi.org/10.1371/journal.pmed.1003228.t004
PLOS MEDICINE Clinical and cost-effectiveness of bariatric surgery in patients with severe T2DM
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003228 December 7, 2020 13 / 22
clinical outcomes and was cost saving when compared to best medical management both in
terms of “upfront” treatment costs and avoidance of future costs of complications. In this, the
largest clinical series to date, two-thirds of patients with T2DM-Ins at baseline ceased use of
insulin after surgery, with one-third ceasing all medication for T2DM. Our data suggest that
these improvements persist for at least 4 years following surgery. These results are comparable
to those of a regional database study which reported that 27% of patients on insulin at baseline
continued to take insulin at 3 years post-RYGB, with 40% off all medication for T2DM [15].
Interestingly, our results are also similar to those reported for patients with both recent and
long-standing T2DM: in a randomised controlled trial 5 years post-RYGB or SG, 35% of surgi-
cal patients had stopped taking all medications for T2DM [4]. Our findings therefore challenge
Table 5. Unadjusted and adjusted RRs for insulin cessation at follow-up by subsequent change in weight and procedure (n = 1,847).
n % on insulin at 6–24 month
follow-up
RR (95% CI)
unadjusted
RR (95% CI) fully adjusted� (WL
model)
RR (95% CI) fully adjusted� (EWL
model)
Operation type
AGB 137 66.4% 0.45 (0.34–0.60) 0.55 (0.40–0.74) 0.56 (0.42–0.73)
RYGB 1,313 28.3% 1 1 1
SG 397 35.5% 0.92 (0.86–0.99) 0.97 (0.90–1.04) 0.97 (0.91–1.04)
p-value� <0.001 <0.001 <0.001
Weight loss (%)
20% or less 369 51.5% 1 1 _
20%–25% 335 36.4% 1.33 (1.17–1.52) 1.21 (1.06–1.38) _
25%–30% 407 31.9% 1.45 (1.27–1.66) 1.33 (1.16–1.51) _
30%–35% 359 23.7% 1.55 (1.36–1.78) 1.37 (1.20–1.57) _
35% or more 377 20.2% 1.53 (1.34–1.74) 1.35 (1.19–1.54) _
p-value† <0.001 <0.001
Excess weight loss (%)
25% or less 75 68.0% 0.51 (0.39–0.67) _ 0.64 (0.51–0.80)
25%–50% 471 40.6% 1 _ 1
50%–75% 825 30.7% 1.16 (1.06–1.27) _ 1.13 (1.04–1.22)
75%–100% 388 22.4% 1.26 (1.15–1.39) _ 1.19 (1.09–1.30)
100% or
more
88 23.9% 1.22 (1.04–1.43) _ 1.19 (1.00–1.40)
p-value† <0.001 <0.001
�p-values test for heterogeneity between categories.
†p-values test for linear trend derived from model where weight loss and excess weight loss were fitted as continuous variables.
AGB, adjustable gastric band; CI, confidence interval; EWL, excess weight loss; RR, relative risk; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; WL, weight
loss.
https://doi.org/10.1371/journal.pmed.1003228.t005
Table 6. Treatment acquisition costs of BS versus BMT.
BS BMT Incremental cost (BS–BMT)
Drug costs (GBP£) 641 10,578 −9,937
Surgery cost (GBP£) 5,544 0 5,544
Total treatment costs (GBP£) 6,185 10,578 −4,393
Costs over 5 years.
BMT, best medical treatment; BS, bariatric surgery.
https://doi.org/10.1371/journal.pmed.1003228.t006
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the popular view that bariatric surgery has limited clinical efficacy for patients with more
advanced T2DM [14].
Our data indicate that in patients requiring insulin for T2DM, AGB is associated with
lower rates of insulin cessation and remission of T2DM than RYGB and SG. Greater weight
loss has been associated with superior T2DM outcomes [16,29], and we found that this holds
true for patients with T2DM-Ins. Moreover, even when adjusted for weight loss, AGB was
associated with lower rates of insulin cessation when compared to RYGB or SG. These findings
support the notion that improvements in T2DM seen after bariatric surgery have both weight
loss–dependent and weight loss–independent components [12,30]. We observed a trend
towards increased insulin cessation over time in the RYGB group, despite weight stability, sug-
gesting a further possible late weight loss–independent effect of RYGB on T2DM.
The major novel finding of this study is that over a 5-year time horizon, the costs of bariat-
ric surgery are predicted to be lower than those of medical management for patients with
T2DM-Ins. Of particular note, the greatest savings stem from direct treatment costs: bariatric
surgery is significantly cheaper than the medications that would otherwise be prescribed to
patients with severe T2DM over a 5-year period. This is an important finding, given that the
majority of previous economic evaluations concluded that the direct treatment costs of surgery
exceeded those of BMT [21,31–33]. The difference may be explained by the fact that previous
studies either predated the widespread adoption of newer pharmacological agents for diabetes
Table 7. Incidence of diabetes-related complications.
BS BMT Incremental difference (BS–BMT)
IHD (%) 3.17 4.12 −0.95
MI (%) 6.02 6.62 −0.60
CHF (%) 2.36 6.43 −4.07
Stroke (%) 1.63 2.06 −0.43
Amputation (%) 0.29 0.67 −0.38
Renal failure (%) 0.42 0.35 0.07
Cumulative incidence over 5 years.
BMT, best medical treatment; BS, bariatric surgery; CHF, chronic heart failure; IHD, ischaemic heart disease; MI,
myocardial infarction.
https://doi.org/10.1371/journal.pmed.1003228.t007
Table 8. Costs of T2DM-related complications.
BS BMT Incremental difference (BS–BMT)
IHD cost (GBP£) 414 542 −128
MI cost (GBP£) 381 362 19
CHF cost (GBP£) 187 491 −304
Stroke cost (GBP£) 283 352 −69
Amputation cost (GBP£) 55 113 −58
Renal failure cost (GBP£) 197 144 52
Other costs� (GBP£) 13,203 12,748 455
Total cost (GBP£) 14,720 14,753 −33
Cumulative cost of complications over 5 years.
�Non-complication costs of treating T2DM.
BMT, best medical treatment; BS, bariatric surgery; CHF, chronic heart failure; IHD, ischaemic heart disease; MI,
myocardial infarction; T2DM, type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pmed.1003228.t008
PLOS MEDICINE Clinical and cost-effectiveness of bariatric surgery in patients with severe T2DM
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003228 December 7, 2020 15 / 22
or focused on patients with early T2DM who are often maintained on relatively inexpensive
single oral agents [20–22].
In terms of adverse events, our financial allocations for surgical complications over the
5-year period are comparable to other models derived from UK data [20,22]; however, the
majority of previous studies evaluating the costs of bariatric surgery versus medical manage-
ment have not included costings for adverse events related to treatment in the medically
treated patients [20,21]. The newer medications in use for T2DM such as GLP-1 RA and
SGLT-2 inhibitors have side effect profiles that require medical attention and treatment in a
proportion of patients [34,35]. Though these adverse medical events do have cost implications,
the adverse events costs for surgical patients are still slightly higher than for patients treated
with BMT in this study.
With regard to avoidance of complications, previous economic evaluations have demon-
strated contradictory results. In the UK, Gulliford and colleagues demonstrated that although
a bariatric surgical strategy in patients with obesity and T2DM had higher expected cost than
medical management, the cost of subsequent clinical gains was sufficiently low to make sur-
gery cost-effective to a healthcare payer (GBP£7,129/QALY gained) [20]. By contrast, Bori-
senko and colleagues found that the avoidance of complications through a surgical strategy in
patients with obesity and T2DM lead to direct healthcare savings [22]. This saving, however,
occurred over a long time horizon (for female patients 10 years and for male patients over a
lifetime). We have demonstrated that not only are there cost savings within the cohort of
patients with T2DM-Ins due to avoidance of future complications, but also these savings occur
over a very short time horizon of less than 5 years. It is likely that the differences between our
study findings and previous analyses are due to the fact that our study was designed to specifi-
cally investigate the sub-cohort of patients with T2DM-Ins, for whom BMT involves expensive
medications.
Our study has some limitations. The NBSR dataset contains limited long-term follow-up:
we attempted to address this issue by mandating a minimum follow-up period. Moreover, it
should be noted that loss to follow-up rate in this study is comparable to other national registry
Table 9. Total costs of bariatric surgery and BMT.
BS BMT Incremental difference (BS–BMT)
Treatment acquisition costs (GBP£) 6,185 10,578 −4,393
Adverse event costs (GBP£) 1,152 955 197
Cost of complications (GBP£) 14,720 14,753 −33
Total costs (GBP£) 22,057 26,286 −4,229
Costs over 5 years.
BMT, best medical treatment; BS, bariatric surgery.
https://doi.org/10.1371/journal.pmed.1003228.t009
Table 10. Cost-effectiveness of bariatric surgery and BMT.
BS BMT Incremental difference (BS–BMT) ICER (cost/QALY) NMB (GBP£) NHB (QALYs)
Costs (GBP£) 22,057 26,286 −4,229 Dominated by BS� 4,731 0.24
Average QALYs 3.18 3.15 0.03
Life years gained in 5 years 4.47 4.43 0.04
�Dominated is a health economic term that describes an intervention which is more beneficial and less costly for patients.
BMT, best medical treatment; BS, bariatric surgery; ICER, incremental cost-effectiveness ratio; NHB, net health benefit; NMB, net monetary benefit; QALY, quality-
adjusted life year.
https://doi.org/10.1371/journal.pmed.1003228.t010
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studies (e.g., [15]), and there is no evidence of any systematic bias with regard to the outcomes
of those who did and did not attend follow-up. Furthermore, it should be noted that the total
number of patients with T2DM-Ins with 4-year follow-up in the present study is larger than
any previously published study. With regard to the comparison of the individual procedures,
this was not a randomised controlled trial, and hence, there were significant size disparities (as
well as potentially clinical and demographic differences) in the cohorts of patients undergoing
AGB, SG, and RYGB. In addition, the NBSR does not include details on the dosage and num-
ber of medications that the patients took before and after surgery; however, it should be noted
that the classification of diabetes status in the database is likely to have underestimated the effi-
cacy of surgery as some patients in remission of diabetes are placed on prophylactic metformin
[36].
With regard to the health economic model, we accept that the lack of HbA1c data in the
NBSR cohort is a significant limitation as it does introduce a degree of uncertainty in our esti-
mates of future diabetes-related complications. In the present study, changes in HbA1c levels
post-surgery in our model were inferred from previous studies. Nonetheless, HbA1c levels
may be less economically important than changes in medications, particularly given our find-
ing that the direct medication costs in the BMT group (as opposed to changes in disease-spe-
cific complication rates) are the most significant factor in the cost saving associated with
bariatric surgery. As with all models, ours was unable to include all variables that may impact
on overall outcomes. For example, our model was not designed to consider the broader cost
implications of weight loss and improvement in T2DM status on occupational productivity.
Additionally, we were unable to incorporate the potential differential effects of bariatric sur-
gery as compared to BMT on lifestyle factors such as physical exercise and mental health status,
which may, in turn, affect health and cost outcomes more broadly. Finally, our time horizon
perspective for cost-effectiveness was deliberately short at 5 years, and therefore there is uncer-
tainty around long-term cost-effectiveness.
It is also worth noting that both medical and surgical treatments for patients with obesity
and T2DM evolve over time: this is true of the available medications and operations, as well as
the evidence regarding their efficacy and side effects. For example, in the surgical group, we
have not analysed the impact of other procedures such as loop gastric bypass as this was infre-
quently performed at the time the data were collected. With respect to BMT, since the time the
model was devised, it has become clear that use of both GLP-1 RA and SGLT2 inhibitors may
confer additional benefits for patients with T2DM in terms of reduction of adverse cardiovas-
cular and renal outcomes [37,38]—future analyses would factor this in.
In summary, this study provides evidence that a strategy of treating patients with obesity
and T2DM-Ins with SG or RYGB is associated with a significant incidence of diabetes
remission and a high incidence of cessation of insulin therapy. Moreover, while previous
economic analyses have suggested that a surgical strategy for T2DM provides clinical bene-
fits but with higher up-front cost to the healthcare payer, this study indicates that for
patients with T2DM-Ins, the total cost to the health payer is reduced following bariatric sur-
gery as compared to BMT over a 5-year time period. This pattern is seen even when the clin-
ical benefits of bariatric surgery over BMT, in terms of avoidance of future complications,
are not considered.
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